Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Jiangsu Recbio Technology Co., Ltd.
ReCOV
Emergency use authorization for ReCOV was received in Mongolia- reported on Mar 21, 2023. Results from the Phase 2 study showed that neutralizing antibody titer levels against Omicron BF.7 and BA.2.75 induced by sequential vaccination of ReCOV were significantly better than those of the mRNA vaccine group- reported on Dec.25 2022.
-
-
03/21/2023
Direct Biologics
ExoFlo
Favorable safety, dosing and efficacy results from the Phase 2 study of ExoFlo in hospitalized COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) were reported on Mar.14, 2023. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for ExoFlo for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19- reported on Apr. 12, 2022.
-
-
03/15/2023
DYADIC INTERNATIONAL INC (
DYAI)
DYAI-100
Dosing of patients in the Phase 1 study of DYAI-100 COVID-19 booster vaccine candidate was completed and no serious adverse events have been reported as on March 7, 2023.
Initial safety and antibody response update expected in Q2, 2023.
-
03/08/2023
Sabizabulin
FDA declined the request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized COVID-19 patients who are at high risk for Acute Respiratory Distress Syndrome (ARDS).- reported on Mar.2, 2023.
-
-
03/06/2023
VLA2001
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinion for the use of VLA2001 in adults 18 to 50 years of age as a booster dose- reported on Feb.23, 2023. Data showed that additional booster dose of VLA2001 in participants who were previously vaccinated with 2 or 3 doses of mRNA COVID-19 vaccine elicited only a marginally increased neutralizing antibody response- reported on Dec.30, 2022.
-
-
03/06/2023
Shionogi & Co., Ltd.
ensitrelvir (S-217622)
Phase 3 study of Ensitrelvir conducted in Japan met primary endpoint- reported on Feb.21, 2022. Ensitrelvir received emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of SARS-CoV-2 Infection- Reported on Nov.22, 2022.
-
-
02/22/2023
Kinarus Therapeutics Holding AG
KIN001- to treat Covid-19
No safety concerns associated with KIN001 were identified in patients who have completed the 2-week treatment regimen in Phase 2 study- reported on Feb.21, 2023. KIN001 showed strong antiviral activity against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5 in pre clinical studies- reported on Dec.6, 2022.
-
-
02/21/2023
The search for treatments to battle the novel coronavirus (COVID-19) is an ongoing process. With the world on alert, pharmaceutical companies around the globe are rapidly developing drugs to help combat this deadly virus. This calendar tracks various Coronavirus Drug companies and COVID-19 Vaccine progress, and lists the companies currently working on drugs against COVID-19.
Understanding the Vaccine Development Process
Vaccines for Covid-19 are produced in a well-defined process. Steps typically include preclinical research, which includes basic studies to determine the safety and efficacy of a potential vaccine; phases 1, 2 and 3 of clinical trials, that involve increasing numbers of volunteers until ultimately large scale trials can confirm safety and efficacy; and finally regulatory review, manufacturing, and distribution. Each step requires specific resources, skills, infrastructure and time before the vaccine is made available to the public.
Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)